Chapter 1290

Yang Rui arrived at the office area of Astra half an hour ahead of schedule, and sat quietly in the lounge, reading his manuscripts.

Giving a lecture in a large company is very polarized. Sometimes, some professors will get extra praise, and sometimes they will get special ridicule.

With a good title, it's usually easier to get the former.

For example, professors from Harvard University, Stanford University, or members of Trinity College, Cambridge, etc. are always more convincing, but not absolutely.

A good example is a professor at Stanford University. Because of the distance, start-ups in Silicon Valley often invite Stanford professors to give lectures. However, those who go may not be recognized by Silicon Valley people. Although many Silicon Valley people were born in the computer department of Stanford University, they are still very hard to ridicule. After years or years of hard work, those Silicon Valley people with rich income are no longer what they look like in school, and they have their own understanding of the real strength of Stanford University professors.

At this time, Stanford professors are not necessarily at the forefront of the industry.

Moreover, the so-called frontier theory they put forward may not be recognized by the industry.

Bosack and Lena, the founders of Cisco,

It can be regarded as an example of the industry taking all. They are masters of computer theory and have made super first-class practice. The development of network technology has laid the initial foundation.

But a closer look at their identities shows that it's not easy for them to do all this. Bosack is the director of the computer center of Stanford computer department, while sandirena is the director of the computer center of business school. In the age of Silicon Valley's underdevelopment, they basically belonged to the first-class scholars in the theoretical field.

Giving a lecture to Astra is not easy either.

For such a large pharmaceutical company, we can not simply regard it as the level of the industry. In this kind of company, there are also hidden dragon and crouching tiger.

Of course, the original researchers of pharmaceutical companies have no sense of existence in front of scholars like Yang Rui. They belong to the bottom of the chain of disdain for scientific research. Whether they are good students or poor students, whether they are undergraduates or doctoral students, if they enter pharmaceutical companies after graduation, they will not make achievements in the forefront of science.

Even if there are some special cases, they are usually not scientists recognized by the mainstream.

The goal of pharmaceutical companies is to find compounds for known targets in the field of G-protein-coupled receptors. The main work of scholars in pharmaceutical companies is to pick up a target in the systematic research after leading scientists have done systematic research. It can be said that researchers in the industry are not even second-line scientists, It can only be called the third line, the so-called achievement translator.

However, companies like Astra, in addition to the original researchers of pharmaceutical companies, inevitably have researchers transferred from the first and second line. Some powerful companies can even recruit Nobel Prize winners.

2008 The Nobel Prize in biology was awarded to lard? Hausen, who won the prize for his research on human papillomavirus, which causes cervical cancer, has a close relationship with AstraZeneca, which can be regarded as one third of AstraZeneca people.

This Nobel Prize is also the most suspected case of Nobel Prize fraud known to Yang Rui. Although there is no conclusive evidence, AstraZeneca pharmaceutical company has indeed played a key role in this Nobel Prize. One of AstraZeneca's directors is a member of the Nobel Prize Committee. Before winning the prize, AstraZeneca acquired a company that developed key components of HPV vaccine and will charge huge patent fees for them.

In addition, the chairman of the five member committee responsible for the selection of Nobel Prize candidates served as the fee consultant of AstraZeneca in 2006. One of the members of the 50 member committee responsible for voting also took money from AstraZeneca in the name of consultant.

AstraZeneca also sponsored two organizations and promotion departments of the Nobel Prize Committee in the past few years. In addition, several members of the Nobel Prize Committee admitted that they were invited to go to China at the expense of the Chinese side to introduce to Chinese officials how the candidates were selected - after 2005, It shows that China at that time had a peep at the Nobel Prize, or it was only AstraZeneca that used China as a platform.

In a word, large pharmaceutical companies, like large military enterprises or large energy enterprises, are all organisms with huge energy. They can play a stronger role in world affairs than most governments of small countries in Asia, Africa and Latin America.

However, large pharmaceutical companies are also a complex complex complex of contradictions. They all have decades or hundreds of years of history. The founder has gone, and it is difficult for the remaining professional managers and shareholders to find a dominant one. It is not a director or chairman who can definitely decide something important.

Yang Rui needs to prove his strength to get a free ride.In front of the Nobel Prize, everyone is equal except Sweden.

"Mr. Yang Rui, it's time.

”Pulitzer came to the lounge and said it quietly.

Yang Rui stood up steadily, laughed and asked, "are there many people coming?"

"About 60 people." Pulitzer said and explained: "Sweden is a country with a small population. It rarely gathers a lot of people like China."

Yang Rui was stunned and couldn't help laughing.

Pulitzer was embarrassed to know that he had said something wrong.

Yang Rui coughed and said, "60 people are very satisfactory."

He is prepared to explain academic issues to researchers, and there are quite a few people who can make up a class. It's not polite to say that there is an academic seminar on GPCR held in China now. It's estimated that there are not even 30 scholars who can understand what he is talking about. To make matters worse, maybe 15 of them are reluctant.

Of course, the king's flag can be seen by looking up, but it takes courage and luck to walk under the king's flag with knee high blood.

60 Many people, neatly sitting in a classroom like conference room, everyone has a chair, is also placed neatly.

It's really neat.

Standing on the platform, Yang Rui could see the chairs as if they were a military parade, with horizontal and vertical screens.

Moreover, unlike domestic lectures, people tend to sit at the back of the class.

Swedes sit one by one from the front to the back, from left to right, and each chair is tense and close together.

The chair is a folding chair, so there is no handle, which makes the big square chair array a little crowded. However, every Swede sits upright, raises his head, and does not make his position different, and tries not to have physical contact with other people.

If he didn't know that this was his temporary request, Yang Ruizhen thought they had rehearsed.

Of course, it can also be said that they have been rehearsed, and the Swedes have been under collective management since childhood.

In addition to the employees of Astra, several members of the Chinese delegation came to attend the lecture, and they only sat in one row.

Yang Rui plans to teach in English, so he doesn't need to come if he doesn't understand.

In fact, you don't have to come to understand English. The content of Yang Rui's lecture has no intersection with most people's research directions.

"Today I want to talk about G protein coupled receptor, and G protein Yang Rui opened the handout on the desk and said, "I want to make a prediction first. In 30 years, the drugs targeting GPCR will reach 50% of the total number of modern drugs. In other words, when pharmaceutical companies develop new drugs in the future, at least one of every two new drugs is targeted at GPCR.... "

Swedes, who used to be very quiet, suddenly became less quiet.

As a very disciplined people, the Swedes are very similar to the Japanese. They all pay attention to not causing trouble to others. However, at this time, some people still can't help shouting: "how can it be?"

This is not a question, and Yang Rui didn't want to answer it. Instead, he continued: "one of the two new drugs is targeting GPCR, which is not enough, because 50% of the total number of modern drugs is 50%... But let's not talk about the future, let's talk about the present, what we can do with GPCR now."

When Yang Rui said that, everyone was quiet.

For researchers at pharmaceutical companies, "what can we do" is the real dry goods.

At this time, Yang Rui is like a pig killer. Pharmaceutical companies do catering. They need to understand how the pig is divided and what is the most suitable part for each part?

At the end of the day, it depends on the quality of the meat whether the spareribs are to be cooked in soup or sweet and sour, and whether the fat meat is to be refined or recycled.

Of course, it's the pharmaceutical companies at the lower Astra level that pay so much attention to it. It's normal for them to do whatever they want.

Yang Rui looked down at his handout and said: "my ion channel laboratory has done in-depth research on G protein coupled receptor, but this aspect is not what I want to talk about today. I want to cut in from a new angle. I call it dynamic mass re measurement. This method is considered in my spare time. It is a small problem, but it is very useful. At present, the most appropriate place is that it can analyze the drug effect of G protein coupled receptor in human primary cells. "As soon as the word "drug effect" comes out, the neat big square suddenly rises and falls like waves.

That's the way the researchers whisper.

……